Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
View Full LandscapeTarget Indication
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Clinical Trial
NCT05367687Last updated: 1/6/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Operative Sedation of Pediatric
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
Hepatocellular Carcinoma
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy